Trials / Active Not Recruiting

Active Not RecruitingNCT04592653

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

Status: Active Not Recruiting
Phase: Phase 1 / Phase 2
Study type: Interventional
Enrollment: 78 (estimated)

Sponsor: Mural Oncology, Inc · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).

Conditions

Advanced Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	Nemvaleukin alfa	IV infusion over 30 minutes
BIOLOGICAL	Pembrolizumab	IV infusion over 30 minutes

Timeline

Start date: 2020-09-30
Primary completion: 2024-07-01
Completion: 2024-12-01
First posted: 2020-10-19
Last updated: 2024-06-07

Locations

6 sites across 2 countries: United States, Spain

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04592653. Inclusion in this directory is not an endorsement.